Neumora Therapeutics Inc. (NMRA), a clinical-stage biopharmaceutical company that entered the public market in 2023, is gearing up for a year filled with data-driven advancements in 2024.
The company is focused on developing novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases. It has a broad pipeline comprising of 3 clinical-stage assets and a couple of preclinical compounds addressing some of the most prevalent brain health disorders.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.